sarpogrelate has been researched along with cilostazol in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barta, J; Dhalla, NS; Kumamoto, H; Sanganalmath, SK; Takeda, N | 1 |
| Barta, J; Dhalla, NS; Edes, I; Kumamoto, H; Sanganalmath, SK; Takeda, N | 1 |
| Diener, HC; Weber, R | 1 |
| Nagai, H; Nakagawa, H; Niki, H; Nishikawa, M; Yamada, K | 1 |
| Choi, SW; Jeong, IS; Jeong, JO; Jin, SA; Kim, JH; Lee, JH; Park, JH; Seong, IW | 1 |
| Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T | 1 |
| Hidaka, S; Kobayashi, S; Kondoh, M; Miyaji, T; Moriya, H; Nakazawa, R; Ohtake, T; Sato, M | 1 |
| Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S | 1 |
| Choi, BH; Kim, G; Kim, SK; Ku, SK; Kwak, MK; Ryu, D | 1 |
1 review(s) available for sarpogrelate and cilostazol
| Article | Year |
|---|---|
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Lactones; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Succinates; Tetrazoles; Thrombosis; Ticlopidine | 2010 |
2 trial(s) available for sarpogrelate and cilostazol
| Article | Year |
|---|---|
Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers.
Topics: Administration, Oral; Adult; Cilostazol; Cross-Over Studies; Endothelium, Vascular; Headache; Humans; Male; Platelet Aggregation Inhibitors; Republic of Korea; Smoking; Succinates; Tetrazoles; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2013 |
Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
Topics: Aged; Aged, 80 and over; Cilostazol; Epoprostenol; Female; Heart Rate; Humans; Male; Microcirculation; Middle Aged; Peripheral Arterial Disease; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Quality of Life; Renal Dialysis; Succinates; Tetrazoles; Treatment Outcome | 2014 |
6 other study(ies) available for sarpogrelate and cilostazol
| Article | Year |
|---|---|
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Failure; Hemodynamics; Male; Myocardial Contraction; Myocardial Infarction; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Succinates; Tetrazoles; Time Factors; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Coronary Occlusion; Cyclic AMP; Disease Models, Animal; Electrocardiography; Epinephrine; Heart Ventricles; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Succinates; Tetrazoles; Time Factors; Up-Regulation | 2008 |
Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Topics: Animals; Aspirin; Cells, Cultured; Cilostazol; Diabetes Mellitus, Experimental; Fibrinolytic Agents; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Male; Platelet Aggregation; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Succinates; Tetrazoles; Thrombosis; Vascular Cell Adhesion Molecule-1 | 2012 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Secondary Prevention; Stroke; Succinates; Tablets, Enteric-Coated; Tetrazoles; Ticlopidine | 2014 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Insurance, Health; Korea; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Succinates; Tetrazoles; Ticlopidine; Treatment Outcome | 2016 |
Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy.
Topics: Animals; Biomarkers, Pharmacological; Cilostazol; Diabetic Nephropathies; Disease Models, Animal; Hypertension, Renal; Kidney; Male; MicroRNAs; Nephritis; Rats, Wistar; Succinates; Tetraspanin 24; Transforming Growth Factor beta1; Treatment Outcome | 2021 |